NASDAQ:UPB Upstream Bio (UPB) Stock Price, News & Analysis $10.88 +0.17 (+1.54%) As of 10:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Upstream Bio Stock (NASDAQ:UPB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Upstream Bio alerts:Sign Up Key Stats Today's Range$10.73▼$11.0850-Day Range$8.56▼$11.8452-Week Range$5.14▼$29.46Volume25,400 shsAverage Volume349,612 shsMarket Capitalization$585.50 millionP/E RatioN/ADividend YieldN/APrice Target$56.50Consensus RatingBuy Company Overview Upstream Bio, Inc. (NASDAQ: UPB) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision immune protease inhibitors for the treatment of inflammatory and fibrotic diseases. The company’s proprietary platform enables selective targeting of key proteases involved in immune cell regulation, with the goal of modulating disease pathways and reducing systemic side effects typically associated with broad-spectrum immunosuppression. Upstream Bio’s pipeline comprises multiple programs in clinical development, including candidates aimed at addressing chronic pulmonary and autoimmune conditions characterized by dysregulated neutrophil and macrophage activity. Research and development efforts leverage deep insights into protease biology to pursue indications with high unmet medical need and to optimize therapeutic profiles across patient populations. Since its inception, Upstream Bio has established collaborations with academic institutions and industry partners to advance its drug candidates. The company is headquartered in the United States and is exploring opportunities for global patient access through strategic licensing and partnership agreements.AI Generated. May Contain Errors. Read More Receive UPB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address UPB Stock News HeadlinesUpstream Bio begins phase 2 COPD trial for verekitugJuly 10, 2025 | uk.investing.comUpstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory PortfolioJuly 8, 2025 | quiverquant.comQTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that you don't want to take with your retirement savings.July 21 at 2:00 AM | GoldCo Precious Metals (Ad)Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)July 8, 2025 | globenewswire.comUPB Upstream Bio, Inc. - Seeking AlphaJune 28, 2025 | seekingalpha.comUpstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody SpaceJune 16, 2025 | tipranks.comUpstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher PotencyJune 15, 2025 | msn.comUpstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI CongressJune 15, 2025 | quiverquant.comQSee More Headlines UPB Stock Analysis - Frequently Asked Questions How have UPB shares performed this year? Upstream Bio's stock was trading at $16.44 at the beginning of 2025. Since then, UPB stock has decreased by 33.8% and is now trading at $10.8850. How were Upstream Bio's earnings last quarter? Upstream Bio, Inc. (NASDAQ:UPB) issued its earnings results on Tuesday, May, 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.02. The business earned $0.57 million during the quarter, compared to analysts' expectations of $0.71 million. When did Upstream Bio IPO? Upstream Bio (UPB) raised $200 million in an IPO on Friday, October 11th 2024. The company issued 12,500,000 shares at $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair served as the underwriters for the IPO. How do I buy shares of Upstream Bio? Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/06/2025Today7/21/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:UPB Previous SymbolNASDAQ:UPB CIK2022626 Webupstreambio.com Phone(781) 208-2466FaxN/AEmployees38Year FoundedN/APrice Target and Rating Average Price Target for Upstream Bio$56.50 High Price Target$75.00 Low Price Target$38.00 Potential Upside/Downside+427.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio47.43 Quick Ratio47.43 Sales & Book Value Annual Sales$2.37 million Price / Sales243.30 Cash FlowN/A Price / Cash FlowN/A Book Value$8.77 per share Price / Book1.22Miscellaneous Outstanding Shares53,790,000Free Float46,500,000Market Cap$576.63 million OptionableN/A BetaN/A 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:UPB) was last updated on 7/21/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.